BioMarin Announces Interim Analysis of INSPIRE Clinical Trial in Pompe Disease, Encouraged By Positive Trends In Trial

By: via Benzinga
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced interim results from INSPIRE, a Phase 2 trial for reveglucosidase alfa, a ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.